TY - JOUR
T1 - Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection
AU - Gatell, José M.
AU - Miró, J. M.
AU - Aznar, E.
AU - Camé, X.
AU - Moreno, V.
AU - Vidal, X.
AU - Podzamczer, D.
AU - Gudiol, F.
AU - Casanova, A.
AU - Clotet, B.
AU - Jou, A.
AU - Miró, J. M.
AU - Gatell, J. M.
AU - Aznar, E.
AU - Vázquez, J. M.Martinez
AU - Ocaña, I.
AU - Camps, I. Ruiz
AU - Cisterna, R.
AU - Santamaria, J. M.
AU - Cosín, J.
AU - Gómez, J.
AU - Vázquez, J. J.
AU - Aguado, A. Gil
AU - Valencia, M. E.
AU - Buzón, L.
AU - Lahoz, J. M.González
AU - Polo, R. M.
AU - Moreno, V.
AU - Zulaica, D.
AU - Arrondo, F. Rodriguez
PY - 1991/1/1
Y1 - 1991/1/1
N2 - © 1991, Lancet Publishing Group. All rights reserved. To assess the efficacy and safety of ribavirin in patients with human immunodeficiency virus (HIV) infection a multicentre, placebo-controlled, prospectively randomised trial was conducted in CDC group III HIV-infected individuals between February, 1988, and October, 1989. Mean treatment time was 39 weeks (range 6-52); 152 individuals were enrolled, of whom 133 could be evaluated. The two treatment groups were similar at baseline and 66% of all subjects had intravenous drug abuse as the main risk factor for HIV infection. Ribavirin was given at a dose of 15 mg/kg daily by mouth (average daily dose 1000 mg). 9 of 67 patients in the placebo group (13-4%) progressed to CDC Groups IVA, C1, or D vs 6 of 66 (9%) in the ribavirin group. Progressions to group IVC2 were 7 (104%) and 9 (13-6%), respectively. These differences are not statistically significant. There were no clinically or statistically significant differences in CD4 cell counts, total lymphocytes, total white cells, or CD4/CD8 ratios between the two groups during treatment, and no clinically important side-effects were noted.
AB - © 1991, Lancet Publishing Group. All rights reserved. To assess the efficacy and safety of ribavirin in patients with human immunodeficiency virus (HIV) infection a multicentre, placebo-controlled, prospectively randomised trial was conducted in CDC group III HIV-infected individuals between February, 1988, and October, 1989. Mean treatment time was 39 weeks (range 6-52); 152 individuals were enrolled, of whom 133 could be evaluated. The two treatment groups were similar at baseline and 66% of all subjects had intravenous drug abuse as the main risk factor for HIV infection. Ribavirin was given at a dose of 15 mg/kg daily by mouth (average daily dose 1000 mg). 9 of 67 patients in the placebo group (13-4%) progressed to CDC Groups IVA, C1, or D vs 6 of 66 (9%) in the ribavirin group. Progressions to group IVC2 were 7 (104%) and 9 (13-6%), respectively. These differences are not statistically significant. There were no clinically or statistically significant differences in CD4 cell counts, total lymphocytes, total white cells, or CD4/CD8 ratios between the two groups during treatment, and no clinically important side-effects were noted.
U2 - 10.1016/0140-6736(91)90003-8
DO - 10.1016/0140-6736(91)90003-8
M3 - Article
VL - 338
SP - 6
EP - 9
IS - 8758
ER -
